Head-to-head evidence
HS-10374 vs SYHX1901
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
HS-10374
Developed by Hansoh Pharmaceutical Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
SYHX1901
Developed by CSPC Ouyi Pharmaceutical Co. and partners
NCT05858047 · Phase 2 · completed
The trial randomized 93 participants to placebo or one of three SYHX1901 doses and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical PASI 75 response at week 12, but no results are available to determine whether the comparison was met.
Next expected readout: April 2027 · NCT06943950 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HS-10374's landscape · SYHX1901's landscape